Working… Menu

Deep Brain Stimulation (DBS) for Depression Using Directional Current Steering and Individualized Network Targeting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03437928
Recruitment Status : Recruiting
First Posted : February 19, 2018
Last Update Posted : November 12, 2020
University of California, Los Angeles
Information provided by (Responsible Party):
Sameer Sheth, Baylor College of Medicine

Brief Summary:

The goal of the study is to address the unmet need of TRD patients by identifying brain networks critical for treating depression and to use next generation precision DBS with steering capability to engage these targeted networks. The study's goal will be achieved through 3 specific aims:

  1. Demonstrate device capability to selectively and predictably engage distinct brain networks
  2. Delineate depression-relevant networks and demonstrate behavioral changes with network-targeted stimulation
  3. Demonstrate that chronic DBS using steered, individualized targeting is feasible and safe for reducing depressive symptoms

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Device: Directional Deep Brain Stimulation Not Applicable

Detailed Description:
Treatment-resistant depression (TRD) is a major worldwide burden. Major depression has a lifetime prevalence of ~15% across developed countries. Up to a third of patients fail to respond adequately to evidence-based treatments, including pharmacological, behavioral, and electroconvulsive therapy. The investigators employ an innovative approach, including subacute invasive neurophysiological monitoring with which they aim to gain insight into the networks underlying depression symptomatology, confirm the ability to predict the effects of precision DBS on network activity, and harmonize these insights to implement network-guided DBS for TRD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Deep Brain Stimulation (DBS) for Depression Using Directional Current Steering and Individualized Network Targeting
Actual Study Start Date : August 20, 2019
Estimated Primary Completion Date : August 19, 2023
Estimated Study Completion Date : August 19, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Directional Deep Brain Stimulation Device: Directional Deep Brain Stimulation
Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation

Primary Outcome Measures :
  1. Changes in depressive symptoms [ Time Frame: 54 to 60 months ]
    Response will be defined as 50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) from baseline. The range is from 0 to 60 and a score higher than 20 indicates moderate to severe depression.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women (non-pregnant) between ages 22 and 70;
  2. DSM-5 diagnosis (assessed by Structured Clinical Interview for DSM-5 Axis I disorders SCID-5) of major depression disorder (MDD) as the primary diagnosis. A current major depressive episode (MDE), recurrent or single episode with first episode before age 60, secondary to nonpsychotic unipolar major depressive disorder;
  3. Chronic illness with current MDE ≥24 months duration and/or recurrent illness with at least a total of 2 lifetime episodes (including current episode >12 months);
  4. Treatment resistance (defined by criteria on the Antidepressant Treatment History Form ATHF): Failure (i.e. persistence of the major depressive episode) to respond to a minimum of four adequate depression treatments from at least two different treatment categories (e.g. SSRIs, SNRIs, TCAs, other antidepressants, lithium-addition, irreversible MAOIs, antidepressant augmentation with an atypical antipsychotic medication);
  5. Previous trial of Electroconvulsive Therapy (ECT) (lifetime): either did not respond, relapsed, poorly tolerated or refused. If refused, will discuss reasons and ensure subject understands relative risks of ECT versus DBS. We will try to enrich sample with patients who had previously shown response to ECT (or another intervention) that was partial or un-sustained;
  6. A prior trial of ketamine will not be required because it is not FDA approved and durable responses have not been demonstrated, nevertheless, subjects will be informed about this possible off-label option;
  7. Symptom severity for Screening: Hamilton Depression Rating Scale-17 item (HDRS17) ≥20;
  8. The HDRS17 must remain greater than or equal to 20 on two separate assessments (at initial screening and 1 week before surgery), over a 1-month period;
  9. Symptom severity for Outcome: Montgomery Asberg Rating Scale (MADRS) ≥27 to be met at assessment one-week pre-op;
  10. Lifetime exposure to minimal 6 weeks of psychotherapy without sustained response;
  11. Normal brain MRI within 3 months of surgery;
  12. Stable antidepressant medication regimen for the month preceding surgery;
  13. Modified mini-mental state examination (MMSE) score ≥ 24;
  14. Normal thyroid stimulating hormone (TSH) level within 12 months of study entry;
  15. Other medical conditions must be stable for at least 6 months;
  16. Able and willing to give informed consent and agree to attend regular clinic visits for at least 12 months following surgery;
  17. Able to have a treating psychiatrist or close relative present for discussions about the study and co-sign informed consent;
  18. Willingness to sign Treatment Contract

Exclusion Criteria:

  1. DSM-5 Axis I Disorders: any lifetime history of psychotic disorder (e.g., schizophrenia, schizoaffective disorder);
  2. Bipolar disorder with rapid cycling and history of manic episode requiring hospitalization within the past 5 years;
  3. Clinically significant Cluster A or B personality disorder;
  4. Active alcohol or substance use disorder within 6 months, excluding nicotine;
  5. Urine drug test positive for illicit drugs;
  6. Current substantial suicidal risk as defined by a plan or clear immediate intent for self-harm, or made a suicide attempt within the last year; or as identified as C-SSRS;
  7. Neurological/Medical condition that makes the patient, in the opinion of the surgeon, a poor surgical candidate (e.g., progressive neurodegenerative disorder, significant cardiopulmonary disorder, need for chronic anticoagulation);
  8. Any history of seizure disorder or hemorrhagic stroke;
  9. Any medical contraindication to surgery such as infection;
  10. Coagulopathy: Bleeding propensity and/or one of the following: INR > 1.5; prolonged activated partial thromboplastin time (aPTT) ≥ 45 sec; platelet count < 100×103/uL;
  11. Uncontrolled hypertension (systolic > 185 mmHg and/or diastolic > 110 mmHg), demonstrated on each of three repeated measurements taken within one hour regardless of whether or not the patient is taking antihypertensive medications.
  12. Participation in another drug, device, or biological trial within 90 days;
  13. Current implanted stimulation devices including cardiac pacemakers, defibrillators, and neurostimulators including spinal cord stimulators and deep brain stimulators;
  14. Pregnant or has plans to become pregnant in the next 24 months;
  15. Anticipated need for MRI;
  16. Need for Diathermy;
  17. Chronic use of anticoagulant or anti-platelet agents that cannot be safely stopped for a sufficient duration (minimum 2.5 weeks) in the peri-operative period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03437928

Layout table for location contacts
Contact: Sameer A Sheth, MD, PhD 713-798-5060

Layout table for location information
United States, California
University of California, Los Angeles Recruiting
Los Angeles, California, United States, 90095
Contact: Dana Levin    310-267-4331   
Contact: Nader Pouratian    310-825-5111   
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Victoria Pirtle    713-798-1717   
Contact: Sameer A Sheth, MD, PhD    713-798-5060   
Principal Investigator: Sameer A Sheth, MD, PhD         
Sponsors and Collaborators
Baylor College of Medicine
University of California, Los Angeles
Layout table for investigator information
Principal Investigator: Sameer A Sheth, MD, PhD Baylor College of Medicine
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sameer Sheth, Associate Professor, Vice-Chair of Clinical Research, Department of Neurosurgery, Baylor College of Medicine Identifier: NCT03437928    
Obsolete Identifiers: NCT03964194
Other Study ID Numbers: H-43036
First Posted: February 19, 2018    Key Record Dates
Last Update Posted: November 12, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Sameer Sheth, Baylor College of Medicine:
Major Depressive Disorder (MDD)
Deep Brain Stimulation (DBS)
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders